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The aim of the study was to evaluate the response rate and safety of weekly paclitaxel (Taxol
s) combination chemotherapy with
UFT (tegafur, an oral 5-fluorouracil prodrug, and uracil at a 1:4 molar ratio) and leucovorin (LV) in patients with advanced gastric
cancer. Patients with histologically confirmed, locally advanced or recurrent/metastatic gastric cancer were studied. Paclitaxel 1-h
infusion at a dose of 100mgm
 2 on days 1 and 8 and oral UFT 300mgm
 2day
 1 plus LV 90mgday
 1 were given starting from day
1 for 14 days, followed by a 7-day period without treatment. Treatment was repeated every 21 days. From February 2003 to
October 2004, 55 patients were enrolled. The median age was 62 years (range: 32–82). Among the 48 patients evaluated for
tumour response, two achieved a complete response and 22 a partial response, with an overall response rate of 50% (95%
confidence interval: 35–65%). All 55 patients were evaluated for survival and toxicities. Median time to progression and overall
survival were 4.4 and 9.8 months, respectively. Major grade 3–4 toxicities were neutropenia in 25 patients (45%) and diarrhoea in
eight patients (15%). Although treatment was discontinued owing to treatment-related toxicities in nine patients (16%), there was no
treatment-related mortality. Weekly paclitaxel plus oral UFT/LV is effective, convenient, and well tolerated in treating patients with
advanced gastric cancer.
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Gastric cancer is the second leading cause of cancer death
worldwide (Roder, 2002). The prognosis is generally poor, with
an overall 5-year survival of approximately 20% in most countries.
The median survival time of patients who presented with advanced
or metastatic diseases and received best supportive care was only
3–5 months (Verdecchia et al, 2003). For decades, gastric cancer
has been considered as a chemo-resistant tumour. With the
introduction of novel drug administration schedules and the
emergence of new chemotherapeutic agents, modern systemic
chemotherapy could achieve an objective response rate of 30–60%
in advanced gastric cancers (Schoffski, 2002). The overall survival
(OS) also improved to a range between 9 and 11 months; however,
significant treatment-related toxicities were usually inevitable
(Ohtsu, 2005). New treatments with better therapeutic index are
needed to improve the outcome.
Weekly infusion of high-dose 5-fluorouracil (5-FU)/leucovorin
(LV), the HDFL regimen, is an effective chemotherapy regimen for
advanced gastric cancer, with a response rate of 33–48% and a
median survival of 9–10 months, and the haematological toxicities
are minimal (Hsu et al, 1997; Lin et al, 1999). It can be safely
applied even to patients with a poor general condition (Yeh and
Cheng, 1998; Lee et al, 2002). For its efficacy and low-toxicity
profile, weekly HDFL per se and HDFL-based new combination
regimens have been extensively evaluated for the treatment of
patients with advanced gastric cancer in Taiwan (Lin et al, 2001;
Chen et al, 2002; Chao et al, 2004; Yeh et al, 2005). However, the
implantation of a central venous catheter is inevitable for these
treatments.
Received 6 February 2006; revised 17 May 2006; accepted 19 May 2006;
published online 27 June 2006
*Correspondence: Dr LT Chen, Institute of Cancer Research, National
Health Research Institutes, Taipei Veterans General Hospital, Ward 191,
No. 201, Sec. 2, Shih-Pai Road, Taipei 112, Taiwan;
E-mail: leochen@nhri.org.tw or AL Cheng, Department of Internal
Medicine and Department of Oncology, National Taiwan University
Hospital, No. 2, Chung-Shan S Rd, Taipei 100, Taiwan;
E-mail: andrew@ha.mc.ntu.edu.tw
14These authors contributed equally to this work.
British Journal of Cancer (2006) 95, 159–163
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sUFT, a combination of tegafur (a prodrug of 5-FU) and uracil in
a 1:4 molar ratio, is a second generation of oral fluoropyrimidine.
Uracil serves as a competitive antagonist for dihydropyrimidine
dehydrogenase, the major catabolic enzyme of 5-FU, to enhance
the concentration and half-life of 5-FU in the circulation.
Pharmacokinetically, orally administered UFT simulates the
continuously intravenous infusion of 5-FU (Meropol et al, 1996;
Ho et al, 1998). On a 28-day schedule, oral UFT monotherapy
could achieve a 20% response rate in advanced gastric cancer
without significant myelosuppression, diarrhoea, and stomatitis
(Anderson and Lokich, 1992; Takiuchi and Ajani, 1998).
Paclitaxel, an antimitotic agent that stabilises microtubules,
exhibits in vitro activity against gastric cancer cells (Caplow et al,
1994). Paclitaxel monotherapy, at a dose range of 200–250mgm
 2
given as either a 24- or a 3-h infusion every 3 weeks, could achieve
a tumour response rate of 17–21% and a median response
duration of 6.5 months in advanced gastric cancer (Ajani et al,
1998; Ohtsu et al, 1998; Yamada et al, 2001; Schoffski, 2002; Ohtsu,
2005). The non-overlapping toxicity profile of paclitaxel and
infusional 5-FU, and the observation of a schedule-dependent
synergism between paclitaxel and 5-FU in human gastric cancer
cells (Yeh et al, 1998), rationalise such a combination to be
evaluated in treating advanced gastric cancers.
We conducted a phase II study of combination chemotherapy of
paclitaxel, UFT, and LV to determine the response rate and toxicity
profile of this combination in patients with advanced gastric
cancer.
PATIENTS AND METHODS
Patients
Eligibility criteria of the patients included (1) pathologically
confirmed, locally advanced (unresectable), recurrent or metastatic
gastric cancer, (2) measurable disease by imaging studies, (3) no
prior chemotherapy except postoperative adjuvant chemotherapy
that had been administrated more than 12 months before entering
into the study, (4) an ECOG (Eastern Cooperative Oncology
Group) performance status p2, (5) age greater than 18 years old,
and (6) adequate hepatic, renal, and bone marrow functions.
Exclusion criteria included (1) pre-existing peripheral neuro-
pathy, (2) pregnancy, breastfeeding, or women of childbearing
potential without adequate contraception, (3) a concurrent or
prior malignancy, (4) central nervous system metastases, (5) active
infection, and (6) concurrent treatments that might interfere with
study evaluation. This study was approved by the ethics committee
of all participating institutes and signed informed consent was
obtained from all patients.
Study design
This was a prospective, multi-centre, phase II clinical trial. The
primary objective was to evaluate the response rate of weekly
paclitaxel combination chemotherapy with UFT and LV in patients
with advanced gastric cancer. The secondary objective was to
determine the time to progression (TTP), OS, and safety.
Chemotherapy protocol
Paclitaxel (Taxol
s, Bristol-Myers Squibb, Princeton, NJ, USA) was
administered as a 1-h continuous intravenous infusion at a dose of
100mgm
 2 on days 1 and 8. To reduce the risk of hypersensitivity
reactions to paclitaxel, all patients were premedicated with 10mg
of dexamethasone, 300mg of cimetidine, and 50mg of diphen-
hydramine intravenous infusion 30min before chemotherapy.
UFT
s (Taiho Pharmaceutical Co. Ltd., Tokyo, Japan)
300mgm
 2day
 1 and LV (Leucovorin
s, Wyeth Farma, SA
Madrid, Spain) 90mgday
 1 were administered orally starting
from day 1 and continuing for 14 days, followed by a 7-day period
off treatment. The total daily dose of UFT was determined and
rounded to the nearest 100mg and divided into three doses given
8h apart. If the total number of tablets could not be evenly divided,
the highest dose was given in the morning and lower doses in the
afternoon or evening. Cycles were repeated every 3 weeks or upon
recovery from toxicities to baseline or grade 1 (except alopecia and
anaemia).
Dose modification
Chemotherapy doses may be reduced or treatment may be delayed
for no more than 2 weeks to allow for patients’ recovery. The dose
of each study drug was reduced stepwise. Level 1 was paclitaxel
80mgm
 2, UFT 250mgm
 2, and LV 90mgday
 1, and level 2 was
paclitaxel 60mgm
 2, UFT 200mgm
 2, and LV 90mgday
 1.A
maximum of two dose-level reductions were allowed per patient.
Any patient who required a reduction of dose to lower than level 2
must be excluded from the treatment protocol. Dose modification
was based on haematological toxicity and on non-haematological
toxicity. At haematological nadir, if the neutrophil count was
o500mm
 3 or platelets o25000mm
 3, the next dose was
reduced by one level. If a haematology test within 72h before
the next cycle indicated that the neutrophil count was
o1000mm
 3 or the platelet count was o100000mm
 3, the next
cycle should be delayed until haematological recovery. Haematol-
ogy test should be performed every week to identify the
haematological recovery. If recovery was not achieved within 2
weeks from the scheduled date of next cycle, the patient must be
taken off study protocol. If haematological recovery was not
achieved before day 8 from the scheduled date, then paclitaxel
administration was skipped on day 8.
Non-haematological toxicities were graded. Paclitaxel adminis-
tration was resumed at the same dose level during a cycle upon
recovery from toxicities to the baseline or grade 1 (except alopecia
and anaemia). If recovery from non-haematological toxicity was
not achieved before day 8 from the scheduled date, the paclitaxel
dose was skipped on day 8 and the next dose was reduced by one
level. For a toxicity greater than grade 2, UFT and LV
administration was interrupted. When the toxicity subsided to
baseline or less than grade 1, administration was resumed.
Treatment was not continued after treatment cycle day 14,
regardless of the number of days the drug has been interrupted.
Evaluation of efficacy and toxicities
Evaluations before chemotherapy included medical history taking,
physical examination, complete blood count, blood chemistry,
chest X-ray, and computed tomography (CT) scan and/or
magnetic resonance imaging (MRI) of abdomen. After starting
protocol treatment, a complete blood count was conducted weekly
and blood chemistry every 3 weeks. Detailed history, physical
examinations, and treatment-related toxicities were recorded
weekly. Tumour size was measured by imaging studies (CT and/
or MRI) every 6 weeks. Tumour response was evaluated according
to the World Health Organization criteria (Miller et al, 1981). All
subjects with tumour responses (complete response (CR) and
partial response (PR)) underwent a confirmatory scan 4 weeks
following the initial documentation. Toxicities were graded
according to the NCI-Common Toxicity Criteria (version 2)
(Trotti et al, 2000).
Statistical analyses
The Simon optimal two-stage design was used (Simon, 1988). The
response rate of interest were P0¼30% and P1¼50%. If objective
tumour responses were observed in more than five of 15 evaluable
patients in the first stage, an additional 31 evaluable patients would
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responders at the end of the second stage, this treatment would be
considered as effective and deserving further investigation, with an
a-value of 0.05 and a b-value of 0.10. Time to progression was
defined as the duration from the date of starting protocol
treatment to the date of documented disease progression or death
by any cause. Overall survival was defined as the duration from the
date of starting protocol treatment to the date of death. Survival
was estimated by Kaplan–Meier analyses.
RESULTS
Patients and treatment
Between February 2003 and October 2004, 55 patients were
enrolled into the study from six medical centres. The major
clinicopathologic characteristics of patients are listed in Table 1.
The median age of the patients was 62 years (range: 32–82). A total
of 343 (median: 6; range: 1–21) cycles of chemotherapy were
given. Median relative dose intensity was 98% (range: 70–100%)
for paclitaxel, 88% (range: 7–100%) for UFT, and 88% (range: 7–
100%) for LV. In total, 96% of the patients received more than 80%
of the intended doses of paclitaxel, and 56% received more than
80% of the intended doses of UFT and LV.
Efficacy
Seven patients were not evaluable for tumour responses: four
patients failed to return to the clinic for tumour measurements,
two patients were found to have no measurable tumours later, and
one patient refused chemotherapy. Among the 48 evaluable
patients, the best tumour response was CR in two patients, PR in
22 patients, stable disease in 20 patients, and progressive disease in
four patients. The overall response rate was 50% (24 out of 48
patients, 95% confidence interval (CI): 35–65%). The response
rates for patients with X80 and o80% of scheduled UFT dose
intensity were 57% (17 out of 30 patients) and 39% (8 out of 18
patients), respectively (P¼0.3715). The median time to tumour
response was 3 (range: 2.1–4.4) months. The median duration of
tumour response was 5.9 (range: 0.4–12.6) months.
On an intention-to-treat analysis, the median follow-up time for
the 55 enrolled patients was 11.7 (range: 1.0–30.0) months. The
median TTP and OS were 4.4 (95% CI: 4.0–6.5) months and 9.8
(95% CI: 8.6–10.7) months, respectively. The Kaplan–Meier
estimated TTP and OS curves are shown in Figures 1 and 2.
Toxicity
All 55 patients were evaluated for toxicities (Table 2). The most
common toxicity was neutropenia, with grade 3–4 neutropenia
observed in 45% of the 55 patients evaluable for toxicity. One
patient developed neutropenic fever and recovered with appro-
priate therapy. Grade 3 sensory neuropathy developed in four (7%)
patients after a median of five cycles of treatment that invariably
improved with discontinuation of chemotherapy. Grade 3–4
diarrhoea was observed in 15% of the patients. Alopecia developed
in 40 patients (73%). Grade 3 sinus tachycardia was noted in 5% of
the patients. Among them, two occurred during infusion of the
paclitaxel and the other was not related to paclitaxel. All recovered
spontaneously. A total of 32 (58%) patients had a dose delay
during treatment. Dose modification was required in 22 (40%)
Table 1 Clinicopathologic features of the patients
Patient number (%)
Total patients 55
Age (years), median (range) 62 (32–82)
Sex: male/female 33/22
ECOG performance
0 4 (7)
1 45 (82)
2 6 (11)
Treatments for primary tumour
No prior therapy 28 (51)
Surgery only 24 (44)
Surgery+adjuvant chemotherapy 2 (4)
Radiotherapy 1 (2)
Disease status
Locally advanced 3 (5)
Recurrence/metastasis 52 (95)
Disease sites
Liver 29 (53)
Lymph nodes 24 (44)
Peritoneum 12 (22)
Gastrointestinal tract 14 (25)
Bone 1 (2)
Lung 3 (5)
Others 11(20)
ECOG¼Eastern Cooperative Oncology Group.
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Figure 1 Time to progression of the 55 patients.
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Figure 2 Overall survival of the 55 patients.
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spatients. Treatment-related toxicity resulted in treatment discon-
tinuation in nine (16%) patients, which were associated with
paclitaxel-related neuropathy in four patients, a delayed recovery
from neutropenia in four patients, and suspicious myocardial
ischaemia (chest pain) in one patient. There was no treatment-
related mortality.
DISCUSSION
In this study, we showed that weekly 100mgm
 2 of paclitaxel plus
daily oral UFT/LV for 2 weeks every 3 weeks is an active
combination chemotherapy regimen for patients with advanced
gastric cancer. The 50% overall response rate of the evaluable
patients (44% on intention-to-treat analyses), a median survival of
9.8 months, and 45% of grade 3–4 neutropenia were compatible
with those achieved with topoisomerase I inhibitor-, taxane-, or
third generation of oral fluoropyrimidine (i.e. TS-1 and capecita-
bine)-based doublet chemotherapy in phase II trials (Schoffski,
2002; Ohtsu, 2005), in which the objective tumour response rate
and median survival ranged from 40 to 76% and from 9 to 12.5
months, respectively. The median survival of this study was also
comparable with those achieved in previous HDFL-based studies
in our institutes (Hsu et al, 1997; Chen et al, 2002; Chao et al,
2004), and not inferior to the 6.1–12.0 months of median survival
of phase II or III studies of current ‘reference’ regimens for
advanced gastric cancers, that is, ECF, FAMTX, FAMTX, ELF, FUP,
FOLFOX6, and DCF (Webb et al, 1997; De Vivo et al, 2000;
Vanhoefer et al, 2000; Louvet et al, 2002; Ajani et al, 2005; Ohtsu,
2005).
Recently, the superior therapeutic index of weekly paclitaxel
compared to the triweekly schedule has been demonstrated in
gastric cancer patients (Ohtsu et al, 1998; Yamada et al, 2001;
Kakeji et al, 2005). With a comparable tumour response rate (22–
23%) for advanced gastric cancer, the grade 3–4 neutropenia of
weekly paclitaxel (80mgm
 2, on days 1, 8, and 15 every 4 weeks)
and of triweekly paclitaxel (200–210mgm
 2, on day 1 every 3
weeks) were 20 and 37–67%, respectively. Weekly paclitaxel plus
either infusional 5-FU or oral fluoropyrimidine have become
popular investigational combinations for advanced gastric cancers
(Ninomiya et al, 2005; Takeyoshi et al, 2005; Ueda et al, 2005; Yeh
et al, 2005). Among these phase II studies, including the current
one, the tumour response rate was quite consistent, ranging from
35 to 50% in chemo-naı ¨ve gastric cancer patients (Ninomiya et al,
2005; Takeyoshi et al, 2005; Yeh et al, 2005). The efficacy
parameters (objective response, TTP, and OS) and toxicity profiles
(esp. grade 3–4 neutropenia) of current regimen were also nearly
identical to those observed in the previous paclitaxel plus
infusional HDFL trial performed by Yeh et al (2005). The
advantage of this oral approach is the alleviation of the
requirement for and the cost of central venous catheter implanta-
tion and the associated inconvenience of infusion pump, which in
turn might improve the quality of life of treated patients. Our
results suggest that, while in combination with weekly paclitaxel,
daily administration of oral UFT/LV might achieve a similar
therapeutic index and ultimately replace intermittent infusional
5-FU/LV treatment for advanced gastric cancer.
Recently, Takeyoshi et al (2005) showed that paclitaxel
80mgm
 2 intravenously on days 1, 8, and 15 every 4 weeks and
doxifluridine (50-dexoy-5-fluorouridine, an intermediate metabo-
lite of capecitabine) 533mgm
 2 orally on days 1–5 per week could
achieve a tumour response rate of 46% with only 12% of grade 3–4
leucopenia in chemo-naı ¨ve patients. Although the results (includ-
ing the unexpected low incidence of myelosuppression) have to be
verified by a large-scale clinical trial, the 5-days-on/2-days-off oral
fluoropyrimidine schedule is of interest. A recent pharmacological
study on surgical specimens from colorectal cancer patients who
had received preoperative 5-days (weekday)-on/2-days (weekend)-
off UFT treatment showed maintenance of a relatively high level of
intratumoral concentration of 5-FU at 48h after the last dose of
UFT (Sadahiro et al, 2001). The schedule was considered to reduce
the incidence of adverse events and to improve treatment
compliance. Can the modification of UFT administration schedule
further improve the therapeutic index of currently weekly
paclitaxel plus UFT/LV regimen deserves further exploration.
Grade 3 sinus tachycardia was noted in 5% of the patients.
Asymptomatic cardiac disturbances have been reported during
paclitaxel infusion (Kamineni et al, 2003). Hypersensitivity to
paclitaxel or coexistence of underlying diseases may be the
aetiologies. The exact cause was unknown. Caution should be
exercised in patients with underlying cardiac diseases and more
prospective studies are needed to assess its cardiotoxicities.
Nowadays, several novel targeted therapeutic agents such as
inhibitors of epidermal growth factor receptor or of vascular
endothelial growth factor, when used in combination with
chemotherapy, have shown promising activity against gastro-
intestinal cancers (Chong and Cunningham, 2005). The low-
toxicity profiles of such agents also provide an excellent chance to
improve the therapeutic index of this active and convenient
regimen for advanced gastric cancer patients.
In conclusion, the combination of weekly paclitaxel and oral
UFT/LV is an active, outpatient-based chemotherapy regimen with
acceptable toxicities. However, for the palliative nature of systemic
chemotherapy in recurrent or metastatic gastric cancer, strategies
to improve the therapeutic index of the current regimen, that is,
modification of drug administration schedule and/or in combina-
tion with novel biological targeted agents, should also be further
explored.
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Table 2 Percentage toxicity of the paclitaxel, UFT, and LV regimen
Patients (n¼55) Cycles (n¼343)
Grade Grade Grade Grade
Toxicity 1–2 3–4 1–2 3–4
Haematological
Neutropenia 25
a 45 36
b 22
Leucopenia 55 18 52 6
Thrombocytopenia 2 2 1 0.6
Febrile neutropenia 4 2 0.6 0.3
Anaemia 42 9 28 2
Gastrointestinal
Nausea 27 0 14 0
Vomiting 20 0 6 0
Diarrhoea 33 15 18 4
Stomatitis 5 0 1 0
Anorexia 35 2 20 0.3
Weight loss 5 0 4 0
Hypoaesthesia 45 7 46 0
Others
Cardiac 7 5 1 1
Fever 2 0 0.3 0
Alopecia 73 0 74 0
LV¼leucovorin.
aAll numbers are percentage of the 55 patients.
bAll numbers are
percentage of the 343 cycles given.
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